Is bone mineral density predictive of fracture risk reduction?
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Bone mineral density (BMD) measurement is a widely available noninvasive means of identifying individuals with osteoporosis and, possibly, those at high risk for fracture. This nonsystematic review examines the relationship between BMD increase and fracture risk reduction in clinical trials evaluating osteoporosis therapy. The trials examined here are predominantly in postmenopausal women. BMD increase correlates poorly with fracture risk reduction in clinical trials of osteoporosis therapy conducted in postmenopausal women. Although BMD may increase with therapy, the increase is not measurable until later, and the overall increase is too small to account for the timing and magnitude of fracture risk reduction. BMD is only one of many contributors to bone strength and fracture risk reduction. Bone strength is derived from bone quantity, which consists of density and size, and bone quality, which, in turn, consists of structure (micro- and macroarchitecture), material properties, and turnover. Data are beginning to accrue suggesting that changes in bone turnover markers may be an accurate predictor of fracture risk reduction. Future research will elucidate the link between changes in bone turnover markers and bone architecture as a measure of osteoporosis treatment efficacy. Until then, physicians will continue to rely on fracture risk reduction data from well-designed clinical trials when judging the efficacy of different treatments for osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Cited by
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Salmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
“Doubts have emerged as to the abilitiy of BMD to predict and mediate fracture risk reduction in patients receiving antiresorptive therapy [53].”
BackgroundMazziotti, G., Bianchi, A., Bonadonna, S., Nuzzo, M., Cimino, V., Fusco, A., De Marinis, L., & Giustina, A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060112 · Cited by 141
Mazziotti, G., Mancini, T., Mormando, M., De Menis, E., Bianchi, A., Doga, M., Porcelli, T., Vescovi, P. P., De Marinis, L., & Giustina, A. (2011) · Pituitary · doi:10.1007/s11102-011-0293-4 · Cited by 98
“Indeed, it is well acknowledged that the relationship between BMD and risk of fracture is complex [25–27].”
Background
Metadata
- Authors
- Cefalu, C. A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2004-01-09
- Volume
- 20
- Issue
- 3
- Pages
- 341-349
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2083201027
- Cited by
- 132
- References
- 11
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is bone mineral density predictive of fracture risk reduction? https://app.cochat.ai/papers/10.1185/030079903125003062
- The paper
- Cefalu, C. A. (2004). Is bone mineral density predictive of fracture risk reduction? Current Medical Research and Opinion. https://doi.org/10.1185/030079903125003062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.